BR9904773A - Anticorpo monoclonal reconhecendo o oligossacarìdeo de ácido siálico n-glicolilado com galactose-glicose em tumores malignos e composição que o contém. - Google Patents

Anticorpo monoclonal reconhecendo o oligossacarìdeo de ácido siálico n-glicolilado com galactose-glicose em tumores malignos e composição que o contém.

Info

Publication number
BR9904773A
BR9904773A BR9904773A BR9904773A BR9904773A BR 9904773 A BR9904773 A BR 9904773A BR 9904773 A BR9904773 A BR 9904773A BR 9904773 A BR9904773 A BR 9904773A BR 9904773 A BR9904773 A BR 9904773A
Authority
BR
Brazil
Prior art keywords
sialic acid
oligosaccharide
galactose
glucose
present
Prior art date
Application number
BR9904773A
Other languages
English (en)
Portuguese (pt)
Inventor
Adriana Carr Perez
Zaima Mazorra Herrera
Luis Enrique Fernandez Molina
Ana Maria Vazquez Lopez
Ailette Mulet Sierra
Rolando Perez Rodriguez
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of BR9904773A publication Critical patent/BR9904773A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
BR9904773A 1998-02-05 1999-02-05 Anticorpo monoclonal reconhecendo o oligossacarìdeo de ácido siálico n-glicolilado com galactose-glicose em tumores malignos e composição que o contém. BR9904773A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU1998022A CU22731A1 (es) 1998-02-05 1998-02-05 Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen
PCT/CU1999/000001 WO1999040119A1 (es) 1998-02-05 1999-02-05 Anticuerpo monoclonal que reconoce el oligosacarido acido sialico n-glicolilado-galactosa-glucosa en tumores malignos y composicion que lo contiene

Publications (1)

Publication Number Publication Date
BR9904773A true BR9904773A (pt) 2000-03-21

Family

ID=5459215

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9904773A BR9904773A (pt) 1998-02-05 1999-02-05 Anticorpo monoclonal reconhecendo o oligossacarìdeo de ácido siálico n-glicolilado com galactose-glicose em tumores malignos e composição que o contém.

Country Status (17)

Country Link
US (1) US6429295B1 (ja)
EP (1) EP0972782B1 (ja)
JP (1) JP4125383B2 (ja)
CN (1) CN1149224C (ja)
AR (1) AR013021A1 (ja)
AT (1) ATE250085T1 (ja)
AU (1) AU764632B2 (ja)
BR (1) BR9904773A (ja)
CA (1) CA2286288C (ja)
CO (1) CO4810341A1 (ja)
CU (1) CU22731A1 (ja)
DE (1) DE69911322T2 (ja)
DK (1) DK0972782T3 (ja)
ES (1) ES2209391T3 (ja)
MX (1) MXPA99009082A (ja)
PT (1) PT972782E (ja)
WO (1) WO1999040119A1 (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004531469A (ja) * 2000-12-08 2004-10-14 チルドレンズ メモリアル ホスピタル 皮膚疾病の治療に使用するガングリオシドを含む組成物
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
US20040115204A1 (en) * 2002-12-11 2004-06-17 Fanger Gary R. Antibodies to treat cancer
CA2510250A1 (en) * 2002-12-20 2004-08-12 Momenta Pharmaceuticals, Inc. Glycan markers for diagnosing and monitoring disease
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
CN101835319B (zh) 2009-03-13 2014-05-07 奥斯兰姆有限公司 用于电子镇流器的外壳
CA3188287A1 (en) 2010-03-26 2011-09-29 Memorial Sloan-Kettering Cancer Center Antibodies to muc16 and methods of use thereof
WO2012075173A2 (en) 2010-12-01 2012-06-07 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
WO2012106368A2 (en) 2011-01-31 2012-08-09 The Regents Of The University Of California Methods for inhibiting prostate cancer
CU24070B1 (es) 2011-12-27 2015-01-29 Ct De Inmunología Molecular Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
CU24120B1 (es) 2012-03-01 2015-08-27 Ct De Inmunología Molecular Anticuerpos recombinantes con especificidad dual por los gangliósidos n-acetil gm3 y n-glicolil gm3
CN104651314B (zh) 2015-02-14 2018-06-19 百泰生物药业有限公司 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子
WO2016149485A1 (en) 2015-03-17 2016-09-22 The Regents Of The University Of California Novel chemoimmunotherapy for epithelial cancer
AU2016233309B2 (en) 2015-03-17 2021-11-18 Memorial Sloan Kettering Cancer Center Anti-MUC16 antibodies and uses thereof
CN109721632B (zh) * 2017-10-27 2023-10-31 齐鲁制药有限公司 一种高纯度神经节苷脂gm1及其制备方法
CU20210104A7 (es) 2021-12-21 2023-07-12 Ct Inmunologia Molecular Proteínas de fusión compuestas por un anticuerpo y una muteína agonista de interleucina 2

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965198A (en) * 1985-12-24 1990-10-23 Konica Corporation Monoclonal antibody and method of manufacturing hybridoma producing the same
EP0491057B1 (en) * 1990-07-10 1998-12-30 Nkk Corporation Hybridoma which produces avian specific immunoglobulin g
DE69428763T2 (de) 1993-12-09 2002-08-01 Ct De Inmunologia Molecular Ci Monoklonale Antikörper gegen Ganglioside und deren Verwendung in der spezifischen, aktiven Immuntherapie gegen bösartige Tumoren

Also Published As

Publication number Publication date
JP4125383B2 (ja) 2008-07-30
AR013021A1 (es) 2000-11-22
DE69911322D1 (de) 2003-10-23
WO1999040119A1 (es) 1999-08-12
AU2407899A (en) 1999-08-23
DK0972782T3 (da) 2004-02-02
MXPA99009082A (es) 2002-04-24
CA2286288C (en) 2010-09-28
JP2001509684A (ja) 2001-07-24
EP0972782B1 (en) 2003-09-17
CU22731A1 (es) 2002-02-28
CA2286288A1 (en) 1999-08-12
EP0972782A1 (en) 2000-01-19
CN1256696A (zh) 2000-06-14
WO1999040119A9 (es) 2000-07-06
ATE250085T1 (de) 2003-10-15
DE69911322T2 (de) 2004-07-01
US6429295B1 (en) 2002-08-06
CN1149224C (zh) 2004-05-12
ES2209391T3 (es) 2004-06-16
CO4810341A1 (es) 1999-06-30
PT972782E (pt) 2004-02-27
AU764632B2 (en) 2003-08-28

Similar Documents

Publication Publication Date Title
BR9904773A (pt) Anticorpo monoclonal reconhecendo o oligossacarìdeo de ácido siálico n-glicolilado com galactose-glicose em tumores malignos e composição que o contém.
Lindner et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein
Visser et al. Labeling of monoclonal antibodies with rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol
Shreve et al. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants
Van Nostrand The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer
Epenetos et al. Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours
Houghton et al. Pretargeted immuno-PET of pancreatic cancer: overcoming circulating antigen and internalized antibody to reduce radiation doses
Colcher et al. Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72. 3) in patients with carcinoma
Sears et al. Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma
Oh et al. False-positive uptake on radioiodine whole-body scintigraphy: physiologic and pathologic variants unrelated to thyroid cancer
Rainsbury et al. Location of metastatic breast carcinoma by a monoclonal antibody chelate labelled with indium-111
Michelot et al. Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl 4-iodobenzamide)
Bischof-Delaloye et al. Clinical value of immunoscintigraphy in colorectal carcinoma patients: a prospective study
Collins et al. Biodistribution of radiolabeled adenosylcobalamin in patients diagnosed with various malignancies
RU2161042C2 (ru) Обнаружение и лечение рака
Stein et al. Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors
Zettlitz et al. A dual-modality linker enables site-specific conjugation of antibody fragments for 18F-immuno-PET and fluorescence imaging
RU2016124229A (ru) Полипептиды антител и их применения
Tang et al. A radiopharmaceutical [89Zr] Zr-DFO-nimotuzumab for immunoPET with epidermal growth factor receptor expression in vivo
Lamki et al. Radioimaging of melanoma using 99mTc-labeled Fab fragment reactive with a high molecular weight melanoma antigen
BR112022019853A2 (pt) Imunoconjugado que se liga especificamente a eno-1, composição para diagnóstico ou imagem de células ou de um tecido que expressa eno-1, composição farmacêutica para uso no tratamento de uma doença inflamatória, método para tratar uma doença inflamatória, e uso do imunoconjugado
Powe et al. Labeling monoclonal antibodies and F (ab') 2 fragments with (111In) indium using cyclic DTPA anhydride and their in vivo behavior in mice bearing human tumor xenografts
Kumar et al. 64Cu-labeled peptide for PET of breast carcinomas expressing the thomsen-friedenreich carbohydrate antigen
Andersson et al. Bile salt malabsorption in the radiation syndrome
Meyer et al. CT evaluation of locally advanced carcinoma of the distal colon and rectum

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2447 DE 28-11-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B15K Others concerning applications: alteration of classification

Ipc: C07K 16/30 (2006.01), A61K 38/00 (2006.0